Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock

Key Points

• Kory James Wentworth, Entrada's CFO, sold 2,500 shares on April 1 at $12.95 for $32,375 under a pre-arranged Rule 10b5-1 trading plan, leaving him with 119,010 shares (a 2.06% decrease). He also sold an additional 24,465 shares in March across three transactions for roughly $312,000, signaling notable recent insider selling.
• TRDA is trading around $13.15 with a market cap near $503 million and a one-year range of $4.93–$13.66; analysts’ consensus is a Moderate Buy with an average price target of $18.50 and institutional ownership of about 86.4%.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 2,500 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total value of $32,375.00. Following the transaction, the chief financial officer owned 119,010 shares of the company's stock, valued at approximately $1,541,179.50. The trade was a 2.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kory James Wentworth also recently made the following trade(s):

• On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.02, for a total transaction of $148,271.76.
• On Monday, March 9th, Kory James Wentworth sold 5,089 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.00, for a total value of $66,157.00.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.25, for a total transaction of $97,853.00.

Entrada Therapeutics Stock Performance

TRDA stock traded down $0.33 during midday trading on Thursday, reaching $13.15. The company's stock had a trading volume of 178,008 shares, compared to its average volume of 225,838. The firm has a market capitalization of $503.38 million, a price-to-earnings ratio of -3.80 and a beta of -0.15. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $13.66. The stock has a fifty day simple moving average of $11.74 and a two-hundred day simple moving average of $9.58.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.38. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. The company had revenue of $1.30 million during the quarter, compared to analysts' expectations of $7.41 million. As a group, analysts forecast that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Institutional Trading of Entrada Therapeutics

Several hedge funds have recently made changes to their positions in the business. State of Wyoming raised its position in Entrada Therapeutics by 130.9% in the 2nd quarter. State of Wyoming now owns 7,575 shares of the company's stock valued at $51,000 after purchasing an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock valued at $51,000 after purchasing an additional 3,707 shares in the last quarter. AXQ Capital LP purchased a new stake in shares of Entrada Therapeutics during the 3rd quarter worth approximately $67,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics during the second quarter worth about $68,000. Finally, Inscription Capital LLC purchased a new stake in Entrada Therapeutics in the third quarter valued at approximately $69,000. Institutional investors and hedge funds own 86.39% of the company's stock.

Analyst Ratings Changes

TRDA has been the subject of several recent analyst reports. Oppenheimer began coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They issued an "outperform" rating and a $21.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of Entrada Therapeutics in a research note on Wednesday. They set an "overweight" rating for the company. Guggenheim upgraded Entrada Therapeutics to a "strong-buy" rating in a research report on Wednesday, February 11th. Wall Street Zen cut Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $18.50.

About Entrada Therapeutics

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.